The evidence base for scaling-up hepatitis C virus (HCV) treatment and harm reduction services within rural communities is limited, and requires a better understanding of the socio-cultural context and operational issues for these distinct settings. Best practices from US urban centers, where most implementation research has been focused, do not necessarily translate to sparsely populated rural areas, where HCV and harm reduction services are limited and fragmented.
Keywords: harm reduction; hepatitis C virus; medication-assisted treatment; opioid use; people who inject drugs; syringe service programs.